Table 1.
Patient characteristics. PS and corticosteroid dose were noted approximately 1 month after surgery when the patient was seen at Department of Oncology, before start on oncologic treatment. adj: adjuvant.
| Number of patients | 108 |
|---|---|
| Sex | |
| Female (%) | 44 (41) |
| Male (%) | 64 (59) |
| Age at diagnosis, median (range) | 62 (18–89) |
| PS, median (%) | 0 (0–4) |
| 0 | 59 (55) |
| 1 | 34 (32) |
| 2 | 13 (12) |
| 3 | 1 (1) |
| 4 | 1 (1) |
| MGMT‐methylated (%) | 48 (44.4) |
| IDH wild‐type (%) | 103 (95) |
| ATRX mutated (%) | 5 (4.6) |
| Corticosteroid dose, mg (median, min‐max) | 15 (0–75) |
| Treatment (%) | |
| RT/TMZ and adj TMZ | 83 (77) |
| RT/TMZ plus IT or placebo (trial) | 6 (6) |
| IT/RT and adj IT (trial) | 4 (4) |
| TMZ monotherapy | 2 (2) |
| 60 Gy/30F | 5 (5) |
| 34 Gy/10F | 7 (7) |
| None | 1 (1) |
| RT/TMZ and adj TMZ completed (%) | 31 (37) |
| Median number of cycles (range) | 5 (0–11) |
| Still on‐treatment at datalock (%) | 6 (7) |
| Relapse surgery (%) | |
| Yes | 43 (40) |
| No | 41 (38) |
| Not yet progressed | 24 (22) |
| Tumor location (%)/ complete resection (%) | |
| Frontal | 33 (31)/ (76) |
| Parietal | 22 (20)/ (91) |
| Temporal | 30 (28)/ (60) |
| Occipital | 8 (7)/ (100) |
| Brainstem | 1 (9)/ (0) |
| Other a | 14 (13)/ (64) |
| PFS, median (months) | 7.8 |
| MGMT‐unmethylated | 6.7 |
| MGMT‐methylated | 13.7 |
| OS, median (months) | 16.3 |
| MGMT‐unmethylated | 14.7 |
| MGMT‐methylated | Not reached |
a
Tumor overlapping two lobes.